Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders

Y. Sawae, Y. Niho, T. Okamura, H. Gondo, M. Kozuru, N. Uike, K. Muta, T. Goto, Y. Suehiro, M. Kumakawa, J. Nishimura, Y. Yufu, H. Ishikura, S. Yamashita, S. Hisano, E. Morioka, H. Nakajima, T. Shibuya, K. Yamasaki, N. Harada & 14 others R. Asayama, S. Hayashi, Koichi Akashi, E. Suematsu, S. Motomura, Y. Yamamoto, T. Takada, K. Ikeda, F. Taguchi, Y. Yamano, M. Taniguchi, E. Matsuishi, Y. Asano, C. Kawasaki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

One hundred and nine patients with infections concurrent with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS) either alone (IPM/CS monotherapy) or in combination with other antimicrobial drugs (IPM/CS combination therapy). The following results were obtained. 1. One hundred and nine patients were allocated at random to two groups: 53 patients to IPM/CS monotherapy and 56 patients to IPM/CS combination therapy. Fourteen patients (6 and 8 in the 2 groups, respectively) were excluded from the clinical evaluation. There were no significant differences between the two groups with respect to the background. 2. The efficacy rates of the 2 treatments against bacterial infections were as follows: in the IPM/CS monotherapy group, 62.5% in 8 patients with sepsis, 75.0% in 23 patients with fever of undetermined origin (FUO), 50.0% in 10 patients with pneumonia, and 68.3% in the 47 patients, and in the IPM/CS combination group, 85.7% in 7 patients with sepsis, 63.6% in 24 patients with FUO, 50.0% in 8 patients with pneumonia, and 67.4% in the 48 patients. The differences between the two groups were not significant. 3. Among the drugs used in combination with IPM/CS, antibiotics other than penicillins, cephalosporins, and aminoglycosides were used in 12 patients and a high efficacy rate of 91.7% was obtained. 4. Bacteriologically, 19 and 17 strains were isolated from the IPM/CS monotherapy and combination therapy groups respectively, and the eradication rates were 100% and 88.9%, respectively. 5. Side effects were noted in 2 patients in the IPM/CS monotherapy group and 7 in the combination therapy group, but all of these resolved after discontinuation or completion of the treatment. The efficacies against severe bacterial infections in the presence of hematopoietic disorders were not different between IPM/CS alone and IPM/CS in combination with other antibiotics. Adverse reactions were uncommon with the monotherapy.

Original languageEnglish
Pages (from-to)1049-1061
Number of pages13
JournalJapanese Journal of Antibiotics
Volume49
Issue number12
Publication statusPublished - Jan 1 1996

Fingerprint

Cilastatin
Bacterial Infections
Pharmaceutical Preparations
imipenem drug combination cilastatin
Group Psychotherapy
Sepsis
Pneumonia
Fever
Aminoglycosides

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders. / Sawae, Y.; Niho, Y.; Okamura, T.; Gondo, H.; Kozuru, M.; Uike, N.; Muta, K.; Goto, T.; Suehiro, Y.; Kumakawa, M.; Nishimura, J.; Yufu, Y.; Ishikura, H.; Yamashita, S.; Hisano, S.; Morioka, E.; Nakajima, H.; Shibuya, T.; Yamasaki, K.; Harada, N.; Asayama, R.; Hayashi, S.; Akashi, Koichi; Suematsu, E.; Motomura, S.; Yamamoto, Y.; Takada, T.; Ikeda, K.; Taguchi, F.; Yamano, Y.; Taniguchi, M.; Matsuishi, E.; Asano, Y.; Kawasaki, C.

In: Japanese Journal of Antibiotics, Vol. 49, No. 12, 01.01.1996, p. 1049-1061.

Research output: Contribution to journalArticle

Sawae, Y, Niho, Y, Okamura, T, Gondo, H, Kozuru, M, Uike, N, Muta, K, Goto, T, Suehiro, Y, Kumakawa, M, Nishimura, J, Yufu, Y, Ishikura, H, Yamashita, S, Hisano, S, Morioka, E, Nakajima, H, Shibuya, T, Yamasaki, K, Harada, N, Asayama, R, Hayashi, S, Akashi, K, Suematsu, E, Motomura, S, Yamamoto, Y, Takada, T, Ikeda, K, Taguchi, F, Yamano, Y, Taniguchi, M, Matsuishi, E, Asano, Y & Kawasaki, C 1996, 'Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders', Japanese Journal of Antibiotics, vol. 49, no. 12, pp. 1049-1061.
Sawae, Y. ; Niho, Y. ; Okamura, T. ; Gondo, H. ; Kozuru, M. ; Uike, N. ; Muta, K. ; Goto, T. ; Suehiro, Y. ; Kumakawa, M. ; Nishimura, J. ; Yufu, Y. ; Ishikura, H. ; Yamashita, S. ; Hisano, S. ; Morioka, E. ; Nakajima, H. ; Shibuya, T. ; Yamasaki, K. ; Harada, N. ; Asayama, R. ; Hayashi, S. ; Akashi, Koichi ; Suematsu, E. ; Motomura, S. ; Yamamoto, Y. ; Takada, T. ; Ikeda, K. ; Taguchi, F. ; Yamano, Y. ; Taniguchi, M. ; Matsuishi, E. ; Asano, Y. ; Kawasaki, C. / Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders. In: Japanese Journal of Antibiotics. 1996 ; Vol. 49, No. 12. pp. 1049-1061.
@article{1376ffe22c9f48e1a3300f4685d71c38,
title = "Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders",
abstract = "One hundred and nine patients with infections concurrent with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS) either alone (IPM/CS monotherapy) or in combination with other antimicrobial drugs (IPM/CS combination therapy). The following results were obtained. 1. One hundred and nine patients were allocated at random to two groups: 53 patients to IPM/CS monotherapy and 56 patients to IPM/CS combination therapy. Fourteen patients (6 and 8 in the 2 groups, respectively) were excluded from the clinical evaluation. There were no significant differences between the two groups with respect to the background. 2. The efficacy rates of the 2 treatments against bacterial infections were as follows: in the IPM/CS monotherapy group, 62.5{\%} in 8 patients with sepsis, 75.0{\%} in 23 patients with fever of undetermined origin (FUO), 50.0{\%} in 10 patients with pneumonia, and 68.3{\%} in the 47 patients, and in the IPM/CS combination group, 85.7{\%} in 7 patients with sepsis, 63.6{\%} in 24 patients with FUO, 50.0{\%} in 8 patients with pneumonia, and 67.4{\%} in the 48 patients. The differences between the two groups were not significant. 3. Among the drugs used in combination with IPM/CS, antibiotics other than penicillins, cephalosporins, and aminoglycosides were used in 12 patients and a high efficacy rate of 91.7{\%} was obtained. 4. Bacteriologically, 19 and 17 strains were isolated from the IPM/CS monotherapy and combination therapy groups respectively, and the eradication rates were 100{\%} and 88.9{\%}, respectively. 5. Side effects were noted in 2 patients in the IPM/CS monotherapy group and 7 in the combination therapy group, but all of these resolved after discontinuation or completion of the treatment. The efficacies against severe bacterial infections in the presence of hematopoietic disorders were not different between IPM/CS alone and IPM/CS in combination with other antibiotics. Adverse reactions were uncommon with the monotherapy.",
author = "Y. Sawae and Y. Niho and T. Okamura and H. Gondo and M. Kozuru and N. Uike and K. Muta and T. Goto and Y. Suehiro and M. Kumakawa and J. Nishimura and Y. Yufu and H. Ishikura and S. Yamashita and S. Hisano and E. Morioka and H. Nakajima and T. Shibuya and K. Yamasaki and N. Harada and R. Asayama and S. Hayashi and Koichi Akashi and E. Suematsu and S. Motomura and Y. Yamamoto and T. Takada and K. Ikeda and F. Taguchi and Y. Yamano and M. Taniguchi and E. Matsuishi and Y. Asano and C. Kawasaki",
year = "1996",
month = "1",
day = "1",
language = "English",
volume = "49",
pages = "1049--1061",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "12",

}

TY - JOUR

T1 - Comparison between monotherapy with imipenem/cilastatin sodium (IPM/CS) and combinations of IPM/CS and other drugs for treating bacterial infections in patients with hematopoietic disorders

AU - Sawae, Y.

AU - Niho, Y.

AU - Okamura, T.

AU - Gondo, H.

AU - Kozuru, M.

AU - Uike, N.

AU - Muta, K.

AU - Goto, T.

AU - Suehiro, Y.

AU - Kumakawa, M.

AU - Nishimura, J.

AU - Yufu, Y.

AU - Ishikura, H.

AU - Yamashita, S.

AU - Hisano, S.

AU - Morioka, E.

AU - Nakajima, H.

AU - Shibuya, T.

AU - Yamasaki, K.

AU - Harada, N.

AU - Asayama, R.

AU - Hayashi, S.

AU - Akashi, Koichi

AU - Suematsu, E.

AU - Motomura, S.

AU - Yamamoto, Y.

AU - Takada, T.

AU - Ikeda, K.

AU - Taguchi, F.

AU - Yamano, Y.

AU - Taniguchi, M.

AU - Matsuishi, E.

AU - Asano, Y.

AU - Kawasaki, C.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - One hundred and nine patients with infections concurrent with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS) either alone (IPM/CS monotherapy) or in combination with other antimicrobial drugs (IPM/CS combination therapy). The following results were obtained. 1. One hundred and nine patients were allocated at random to two groups: 53 patients to IPM/CS monotherapy and 56 patients to IPM/CS combination therapy. Fourteen patients (6 and 8 in the 2 groups, respectively) were excluded from the clinical evaluation. There were no significant differences between the two groups with respect to the background. 2. The efficacy rates of the 2 treatments against bacterial infections were as follows: in the IPM/CS monotherapy group, 62.5% in 8 patients with sepsis, 75.0% in 23 patients with fever of undetermined origin (FUO), 50.0% in 10 patients with pneumonia, and 68.3% in the 47 patients, and in the IPM/CS combination group, 85.7% in 7 patients with sepsis, 63.6% in 24 patients with FUO, 50.0% in 8 patients with pneumonia, and 67.4% in the 48 patients. The differences between the two groups were not significant. 3. Among the drugs used in combination with IPM/CS, antibiotics other than penicillins, cephalosporins, and aminoglycosides were used in 12 patients and a high efficacy rate of 91.7% was obtained. 4. Bacteriologically, 19 and 17 strains were isolated from the IPM/CS monotherapy and combination therapy groups respectively, and the eradication rates were 100% and 88.9%, respectively. 5. Side effects were noted in 2 patients in the IPM/CS monotherapy group and 7 in the combination therapy group, but all of these resolved after discontinuation or completion of the treatment. The efficacies against severe bacterial infections in the presence of hematopoietic disorders were not different between IPM/CS alone and IPM/CS in combination with other antibiotics. Adverse reactions were uncommon with the monotherapy.

AB - One hundred and nine patients with infections concurrent with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS) either alone (IPM/CS monotherapy) or in combination with other antimicrobial drugs (IPM/CS combination therapy). The following results were obtained. 1. One hundred and nine patients were allocated at random to two groups: 53 patients to IPM/CS monotherapy and 56 patients to IPM/CS combination therapy. Fourteen patients (6 and 8 in the 2 groups, respectively) were excluded from the clinical evaluation. There were no significant differences between the two groups with respect to the background. 2. The efficacy rates of the 2 treatments against bacterial infections were as follows: in the IPM/CS monotherapy group, 62.5% in 8 patients with sepsis, 75.0% in 23 patients with fever of undetermined origin (FUO), 50.0% in 10 patients with pneumonia, and 68.3% in the 47 patients, and in the IPM/CS combination group, 85.7% in 7 patients with sepsis, 63.6% in 24 patients with FUO, 50.0% in 8 patients with pneumonia, and 67.4% in the 48 patients. The differences between the two groups were not significant. 3. Among the drugs used in combination with IPM/CS, antibiotics other than penicillins, cephalosporins, and aminoglycosides were used in 12 patients and a high efficacy rate of 91.7% was obtained. 4. Bacteriologically, 19 and 17 strains were isolated from the IPM/CS monotherapy and combination therapy groups respectively, and the eradication rates were 100% and 88.9%, respectively. 5. Side effects were noted in 2 patients in the IPM/CS monotherapy group and 7 in the combination therapy group, but all of these resolved after discontinuation or completion of the treatment. The efficacies against severe bacterial infections in the presence of hematopoietic disorders were not different between IPM/CS alone and IPM/CS in combination with other antibiotics. Adverse reactions were uncommon with the monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0030455893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030455893&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 1049

EP - 1061

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 12

ER -